Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Retained Earnings (2016 - 2026)

Champions Oncology has reported Retained Earnings over the past 16 years, most recently at -$80.4 million for Q1 2026.

  • For Q1 2026, Retained Earnings fell 2.94% year-over-year to -$80.4 million; the TTM value through Jan 2026 reached -$80.4 million, down 2.94%, while the annual FY2025 figure was -$79.9 million, 5.56% up from the prior year.
  • Retained Earnings for Q1 2026 was -$80.4 million at Champions Oncology, roughly flat from -$80.1 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$71.6 million in Q1 2022 and troughed at -$84.6 million in Q2 2024.
  • A 5-year average of -$78.6 million and a median of -$79.9 million in 2023 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: decreased 13.33% in 2023 and later grew 7.56% in 2025.
  • Year by year, Retained Earnings stood at -$72.3 million in 2022, then decreased by 13.33% to -$82.0 million in 2023, then dropped by 0.79% to -$82.6 million in 2024, then increased by 3.0% to -$80.1 million in 2025, then decreased by 0.35% to -$80.4 million in 2026.
  • Business Quant data shows Retained Earnings for CSBR at -$80.4 million in Q1 2026, -$80.1 million in Q4 2025, and -$80.4 million in Q3 2025.